-
Exciting Progress: Corvus Pharmaceuticals Poised to Share Promising Data on Soquelitinib for Atopic Dermatitis
NASDAQ: $CRVS Pharmaceutical research is a journey of meticulous steps, and today, the spotlight shines brightly on Corvus Pharmaceuticals as they prepare to share significant updates from their ongoing clinical investigations. Specifically, the market and the patient community are eagerly anticipating the forthcoming announcement regarding the results from Cohort 4 of the placebo-controlled Phase 1…
-
A New Dawn for DLBCL Treatment? Analyzing Incyte’s Promising Tafasitamab Data
NASDAQ: $INCY The landscape of hematologic oncology is constantly evolving, and recent news from Incyte has sent ripples of excitement through the medical community. Specifically, the announcement of positive topline results from a pivotal study of tafasitamab (marketed as Monjuvi/Minjuvi) as a first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) signals a potentially significant step…
-
Regenxbio Charts Course for 2026: A Deep Dive into Duchenne Gene Therapy Milestones and Promising Long-Term Data
NASDAQ: $RGNX Biotechnology is often a story of patience, rigorous science, and the relentless pursuit of life-changing therapies. Nowhere is this more evident than in the field of gene therapy, especially concerning devastating conditions like Duchenne Muscular Dystrophy (DMD). Regenxbio, Inc. (NASDAQ: $RGNX) has recently provided a significant update, illuminating a clear roadmap toward crucial…
-
Decoding Tenax Therapeutics’ Latest Update: What the Blinded Sample Size Assessment Really Means
NASDAQ: $TENX Unpacking the Latest News from Tenax Therapeutics The world of clinical trials is often shrouded in complexity, full of acronyms and technical jargon that can leave even seasoned investors scratching their heads. Recently, a press release from Tenax Therapeutics ($TENX) caught the attention of the biotech community, specifically concerning the results of a…
-
NRx Pharmaceuticals Achieves Debt-Free Status Ahead of Drug Approvals
NASDAQ: $NRXP Summary of the Article/Press Release On December 18, 2025, NRx Pharmaceuticals, Inc. (Nasdaq: $NRXP), a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders like suicidal depression and PTSD, announced that it has fully eliminated its balance sheet debt. CEO Dr. Jonathan Javitt thanked Anson Funds for their support during tough…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: $AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…